16 exclusive Chinese patent medicines to grab the TOP20!

Recently, there have been frequent developments in the field of new Chinese patent medicines: Kang Enbei received 100 million hollyhock flower total flavonoids oral patch, Tianjin Dongfang Huakang’s Yiqi Tongqiao pills were approved.

Rise across the board! Pediatric Chinese patent medicine increased by 87%, Yang Zijiang became the "big brother"

Sales of proprietary Chinese medicines in public hospitals in key cities (unit: ten thousand yuan)

Source: Mi Nei.

Affected by the epidemic and policies, the market size of proprietary Chinese medicines in public hospitals in key cities will decline significantly in 2020, of which Q1 will decline by nearly 30% in 2020

From the perspective of medication route, internal medication is still the main medication route of proprietary Chinese medicine in public hospitals in key cities, and the market share is increasing year by year, with capsules being the mainstay; injections are the second, but the market is decreasing year by year

2021 H1 Key City Public Hospitals Top 10 Chinese Patent Medicine Treatment Categories

Source: Competitive landscape of public hospitals in key cities of Meinenet

Among the 13 treatment categories of Chinese patent medicines, cardio-cerebrovascular disease drugs are firmly ranked first, but their market share is declining year by year; tumor disease drugs have a market share of 14.

In terms of sales growth rate, 13 treatment categories all showed positive growth compared to the same period last year.

2021 H1 Key City Public Hospitals Top 3 Chinese Proprietary Medicine Manufacturers

Source: Competitive landscape of public hospitals in key cities of Meinenet

From the perspective of the competitive landscape of manufacturers (in terms of the group), Yangzijiang Pharmaceutical, Buchang Pharmaceutical, and Yiling Pharmaceutical rank among the TOP3 manufacturers, with a combined market share of nearly 10%

The top of the list changed hands, 16 exclusive Chinese patent medicines seized the TOP20

2021 H1 key city public hospitals TOP10 products of proprietary Chinese medicines

Note: with * is an exclusive product

Source: Competitive landscape of public hospitals in key cities of Meinenet

In 2021, the sales of TOP20 products of proprietary Chinese medicines in public hospitals of H1 key cities will exceed 100 million yuan, and the total sales scale will exceed 3 billion yuan

Four products including Bailing Capsules, Kanglaite Injection, Danshen Polyphenolate for Injection, and Jinshuibao Tablets have sales of more than 200 million yuan

16 are exclusive products (including exclusive dosage forms), including Suhuang Cough Capsules and Lanqin Oral Liquid from Yangtze River Pharmaceuticals, Danhong Injection and Naoxintong Capsules from Buchang Pharmaceuticals, Bailing Capsules from Sino-US East China, Zhejiang Kang Wright KLT, Green Valley pharmaceutical injection with salvianolate like

From the perspective of the treatment field, 20 products involve 5 treatment categories, focusing on drugs for cardiovascular and cerebrovascular diseases (8) and drugs for tumor diseases (5)

In terms of growth rate, 12 products showed a positive growth over the same period last year, of which 7 had a growth rate of more than 10%.

Renfu, Jianmin, Fangsheng.

New Chinese patent medicines approved for marketing since 2021

Source: Meinenet MED2.

The "three anti-epidemic prescriptions" Qingfei Paidu Granules, Huashi Baidu Granules, and Xuanfei Baidu Granules are effective prescriptions that are innovatively based on ancient classics.

Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets (previously used names: Yizhi Anshen Tablets, Bailing Anshen Tablets) are based on the Chinese Tongluo Health Eight Character Classic to guide the pathogenesis of insomnia and are developed on the basis of clinical experience.
The new traditional Chinese medicine compound preparation of the Chinese medicine provides a new treatment option for patients with insomnia
.

In recent years, with the support of a series of encouraging policies, the exploration of centralized procurement of Chinese patent medicines at different provinces has been superimposed, and certain progress has been made in the research and development of innovative Chinese patent medicines
.
At present, 10 new class 1 Chinese patent medicines have submitted marketing applications and are in the status of "under review and approval".
From the perspective of the contract time, they will be concentrated in 2020 and 2021
.

Class 1 new medicines of proprietary Chinese medicines that have been reported for production and are under review

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

A number of Class 1.
1 Chinese medicines have been inspected on the production site, including Yinqiao Qingre tablets from Kangyuan Pharmaceuticals, Jingule tablets from Fangsheng Pharmaceuticals, Qihuang Capsules from Shandong Phoenix Pharmaceuticals, Liwei Capsules from Jianmin Pharmaceuticals, and Yili Pharmaceuticals If progress goes well, such as Huzhen Qingfeng Capsules, these varieties are expected to be approved for marketing in the near future
.

In the field of anti-tumor, Akoladine is an active drug monomer extracted, separated and purified from Epimedium.
It is used to treat advanced liver cancer.
It is considered to be another major breakthrough in the modernization of traditional Chinese medicine after artemisinin
.

In the field of gynecology, Kunyining Granules is a new traditional Chinese medicine developed by modern technology.
It has the characteristics of small dosage, high content of active ingredients, and rapid onset of action.
Good effect
.

In the field of nervous system, Suxia Jieyu Chufan Capsule has the effects of clearing away heat and trouble, relieving depression and resolving phlegm.
It is suitable for people with mild or moderate depression, qi stagnation and phlegm obstruction, and internal disturbance of depression and fire.
Symptoms include depression, upset and restlessness.
, anxiety, fear, tension, insomnia, dizziness, tinnitus, loss of appetite, mouth and throat pain and so on
.

In the field of skeletal muscles, Jingule tablets are a prescription for the etiology of osteoarthritis with local pain and unfavorable activities
.
It has been used in hospitals and civilians for nearly 20 years .
The product has the effects of promoting blood circulation and relaxing muscles, tonifying the veins and relieving pain, invigorating the kidneys and strengthening the bones.
It is suitable for osteoarthritis with stasis of muscles and veins, symptomatic joint pain, swelling, unfavorable activities, numbness of the limbs, sore waist and knees
.

Source: Mi Nei Net Database

Note: The statistics are as of September 26, if there are any omissions, please correct me!